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Pulmonary arterial hypertension (PAH) is characterised by remodelling of
the pulmonary vasculature leading to right ventricular hypertrophy. Here,
we show that miR-322-5p (the rodent orthologue of miR-424-5p) expres-
sion is decreased in the right ventricle of monocrotaline-treated rats, a
model of PAH, whereas a putative target insulin-like growth factor 1
(IGF-1) is increased. IGF-1 mRNA was enriched 16-fold in RNA immuno-
precipitated with Ago2, indicating binding to miR-322-5p. In cell transfec-
tion experiments, miR-322-5p suppressed the activity of a luciferase
reporter containing a section of the IGF-1 30 untranslated region (UTR) as
well as IGF-1 mRNA and protein levels. Taken together, these data sug-
gest that miR-322 targets IGF-1, a process downregulated in PAH-related
RV hypertrophy.
Pulmonary arterial hypertension (PAH) is a patho-
physiological process characterised by high, precapil-
lary pulmonary vascular resistance [1]. PAH can be
idiopathic, heritable (mainly associated with defects in
bone morphogenetic protein receptor 2) or associated
with an underlying condition [2]. The pathology of
PAH is largely consistent irrespective of aetiology and
involves significant vascular remodelling and restric-
tion causing a reduction in cross-sectional area to pul-
monary blood flow, which can lead to right ventricular
hypertrophy [3] and failure [4]. Prognosis for patients
varies, with average survival rates of 58–67% 3 years
after diagnosis for idiopathic PAH [5,6], with cause of
death normally being attributed to right ventricular
failure [7]. One widely used model of PAH is
monocrotaline (MCT) treatment of rats [8]. In this
model, following a single dose of MCT the animals
develop elevated pulmonary vascular resistance leading
to right heart hypertrophy within 4 weeks [9].
Under normal conditions, adult heart size is main-
tained but can change in response to either increased
or reduced load resulting in hypertrophy or atrophy,
respectively. As adult cardiac cells do not divide,
change in heart size is achieved by altering the size of
cardiac myocytes rather than their number. The rela-
tive rates of protein synthesis and breakdown
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contribute to the maintenance of cell size [10,11].
When these are in balance, cell size is maintained; con-
sequently, the RV cardiomyocyte hypertrophy
observed in PAH requires the rate of protein synthesis
to exceed that of protein breakdown.
Insulin-like growth factor-1 is a growth factor that
promotes synthesis and inhibits protein breakdown in
both cardiac and skeletal muscle. Following binding to
its receptor, IGF-1 activates protein kinase B (Akt) via
phosphatidylinositide 3-kinase (PI3K) stimulation [12].
This signalling system contributes to physiological car-
diac hypertrophy, with knockout animals for both Akt
and PI3K showing attenuated heart enlargement
[13,14]. Furthermore, mice that overexpress a dominant
active PI3K demonstrated increased heart size that did
not become maladaptive [15]. However, it is possible
that IGF-1 also contributes to pathological hypertrophy
in combination with other factors, as treatment of salt-
sensitive Dahl rats with IGF-1 reduced survival and
promoted left ventricular dysfunction [16]. Further-
more, IGF-1 deficiency alleviates cardiac hypertrophy
in a model of abdominal aortic constriction [17].
The signalling pathways which contribute to protein
turnover and cell maintenance are regulated in part by
microRNAs, short noncoding RNAs that downregu-
late protein expression via translational repression or
mRNA degradation [18]. The roles of many miRNAs
in the regulation of cardiac mass have previously been
studied; for instance, knockdown of miR-133, which
targets Cdc42 and RhoA, causes significant hypertro-
phy in vivo [19], whereas inhibition of miR-27b, which
targets peroxisome proliferator-activated receptor-c
(PPAR-c), attenuates cardiac hypertrophy [20]. miR-
322-5p is the rodent orthologue of miR-424-5p, a
miRNA from the 424/542 cluster located on the X
chromosome, which has been shown to target the insu-
lin-like growth factor 1 receptor (IGF-1R) in mam-
mary tissue [21] and cardiac muscle [22]. Expression of
miR-322 has previously been shown to be reduced in
the lung of monocrotaline-treated rats. Following
intranasal delivery of miR-322 to the rats, RV systolic
pressure and RV weight were shown to be significantly
reduced compared to controls, suggesting restoring
expression could ameliorate the effects of PAH on the
RV [23]. Importantly, expression of the miRNA in the
hearts of these animals was not reported.
Insulin-like growth factor-1 is a predicted target for
miR-322-5p based on database algorithms, which
match miRNA sequences to putative mRNA targets.
We therefore hypothesised that MCT treatment would
alter miR-322 expression in the right ventricle




Monocrotaline or PBS was administered to 6- to 8-week-
old rats via s.c. injection (40 mgkg1), and 4 weeks later,
pulmonary arterial pressure was measured as previously
described before the animals were humanely sacrificed [24].
The hearts were removed, the right ventricle was dissected
free from the left ventricle and septum and both compo-
nents were weighed and then snap-frozen.
RNA extraction and RT-qPCR
Right ventricles were crushed in TRIzol for RNA extraction
as previously described [25]. Cell RNA extractions were per-
formed using the TaKaRa CellAmp Direct RNA kit (Clon-
tech Saint-Germain-en-Laye, France) as per the
manufacturer’s protocol. For miR-322-5p measurements,
RNA was reverse-transcribed (RT) using miR-322-5p and U6
Applied Biosciences TaqMan primers suspended in 1x TE
buffer as per the manufacturer’s instructions. cDNAwas used
for qPCR with TaqMan fluorescent probes for miR-322-5p
and U6 according to the manufacturer’s instructions. mRNA
was measured via Omniscript RT (Qiagen, Manchester, UK)
with random primers (Promega, Madison, WI, USA) as per
the manufacturer’s protocol. cDNA was diluted 1/10 with
deionised water and used in qPCRs with QuantiFast SYBR
Green (Qiagen) and specific primers (Sigma, Poole, Dorset,
UK) for targets of interest as previously described [26].
Cell culture and transfection
C2C12 mouse myoblasts were cultured in DMEM (Sigma)
supplemented with 10% fetal bovine serum (FBS) and 1%
Pen-Strep (Gibco, Gaithersburg, MD, USA) as previously
described [27]; LHCN-M2 human myoblasts were cultured in
human skeletal muscle medium (PromoCell, Heidelberg, Ger-
many) supplemented with 20% serum (15% FBS and 5%
manufacturer’s serum) as previously described [28]. Cells
were transfected once ~70% confluent with miRNA mimic
and/or antagomir (miRVana) and Lipofectamine 2000 (Invit-
rogen, Paisley, UK) using Opti-MEM (Gibco) as recom-
mended by the manufacturer and as previously described
[27]. Transfected miR-mimic concentrations were kept the
same in all reactions by addition of control miRNA mimic as
appropriate.
Protein isolation from cells and RISC
immunoprecipitation
Forty-eight hours after transfection, C2C12s were lysed in
1x cell lysis buffer (Cell Signalling Technologies, Hitchin,
UK) supplemented at 1/100 with protease inhibitor cocktail
(Sigma). Samples were centrifuged at 12 000 g and
340 FEBS Open Bio 8 (2018) 339–348 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
miR-322-5p targets IGF-1 and is reduced in PAH M. Connolly et al.
supernatant transferred to clean microcentrifuge tubes. Pro-
tein-G-bound Sepharose beads were added to the lysate,
and the tubes were rotated for 2 h at 4 °C for lysate pre-
clearing. Beads to be used for the pull-down were blocked
using 1 mgmL1 salmon sperm DNA (Sigma) under rota-
tion for 2 h at 4 °C. Blocked beads were washed in cell
lysis buffer and the precleared lysate added. Antibodies for
the immunoprecipitation, anti-Ago2 (Millipore, Watford,
UK) or control anti-mouse IgG (Invitrogen), were added at
matching concentrations of 1 : 100 and the samples rotated
overnight at 4 °C. Beads were then washed several times in
cell lysis buffer and PBS before TRIzol RNA extraction as
detailed above.
Secreted IGF-1 measurements (western blot and
ELISA)
Forty-eight hours after transfection, cells were placed into
serum-free medium for 24 h. The medium was collected
and cleared of cell debris by centrifugation at 12 000 g at
4 °C for 20 minutes. The supernatant was transferred to
new tubes and kept on ice. Secreted IGF-1 quantification
was performed first by ELISA (R&D Systems, Abingdon,
UK) as per the manufacturer’s instructions and secondly
via western blot following acetone precipitation (as previ-
ously described [25]). Total protein concentration in the
collected medium was determined via Bradford assay (Bio-
Rad, Watford, UK). ELISA IGF-1 values were then nor-
malised to the total secreted protein, and western blot
images were normalised to Ponceau S-stained membranes.
pMIR-REPORT luciferase assay
A section of the 30UTR of IGF-1 was TA-cloned into
pGEM-T Easy (Promega) using primers: forward (50–30)
GGGACTAGTGAGGAGCCTCCCACGGAGCA, reverse:
(50–30) CCCACTAGTGCTACGTGGGAAGAGGTGA
AG. SpeI digestion was performed and the UTR sequence
ligated into a pMIR-REPORT expression vector (Thermo-
Fisher). Final products were confirmed by sequencing. For
luciferase assays, cells were transfected with luciferase
reporter vectors (pRLTK used as a control) 24 h after
miRNA transfection using standard Lipofectamine
(Invitrogen) and the assay performed as previously
described [27].
Statistics
Animal experiments were conducted in two groups for a
total of nine MCT-treated and nine PBS-treated animals.
Differences between groups were calculated using Student’s
t-test for normally distributed data or by Mann–Whitney
U-test for nonparametric data (GraphPad PRISM, La
Jolla, CA, USA). In vitro mRNA expression data shown
were produced in three independent experiments, with each
experiment consisting of six independent transfections
assayed in duplicate. Box plots are expressed as median
with min–max bars. In vitro protein expression data shown
via western blot are three independent experiments from
six-well plates, and via ELISA are three independent exper-
iments, with each with each experiment consisting of six
independent transfections. RISC IP was performed twice.
Results
MCT rat model: miR-322 and IGF-1 are inversely
expressed in the RV
Nine MCT-treated and nine PBS-treated rats were sac-
rificed after 4 weeks and markers of disease severity
measured to determine PAH development in the two
groups. Pulmonary arterial pressure (PAP) was higher
in the MCT-treated animals compared to controls sug-
gesting increased vascular resistance (Fig. 1A). Right
heart weight (right ventricle/(left ventricle + septum))
was higher in the MCT rats compared to controls,
confirming the development of RV hypertrophy
(Fig. 1B). Quantification of miR-322-5p in the right
ventricles (RVs) showed a 2.6-fold decrease
(P = 0.0004) in miRNA expression in MCT-treated
rats compared to PBS-treated controls (Fig. 1C). Con-
versely, IGF-1 expression was significantly increased in
the RVs of MCT rats compared to PBS controls (3.5-
fold, P = 0.0028), suggesting an upregulation of IGF-1
signalling promoting growth (Fig. 1D).
miR-322 directly targets IGF-1
Bioinformatic analysis predicted IGF-1 to be a target
of both miR-424-5p and its mouse orthologue miR-
322-5p. The mouse IGF-1 gene has seven potential
binding sites for miR-322-5p in its 30UTR, shown in
Fig. 2A. Region A was used for reporter cloning as
the entire seed sequence is complimentary in this sec-
tion. The human IGF-1 gene has three potential bind-
ing sites for miR-424-5p in the UTR, and one in the
coding region, a feature more commonly found in
miRNA containing a 50 AGCAGC motif [29]
(Fig. 2A). To determine whether miR-322-5p targets
IGF-1 in myoblasts, we performed an Ago2 immuno-
precipitation followed by RT-qPCR using cells trans-
fected with a miR-322-5p mimic or a scrambled
control. This analysis showed IGF-1 mRNA was
enriched >16-fold in RNA immunoprecipitated from
miR-322-5p-transfected cells compared to controls
(Fig. 2B). To confirm targeting of IGF-1, the region
of the 30UTR of IGF-1 containing the putative
miRNA-binding site was cloned into pMIR-REPORT
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(Fig. 2A) and the effect of miR-322-5p on luciferase
activity determined in C2C12 cells. Luciferase activity
was significantly reduced in miR-322-5p-transfected
cells compared to controls (Fig. 2C), confirming miR-
322-5p binding to the 30UTR of IGF-1.
miR-322-5p reduces IGF-1 mRNA expression
To determine the effect of miR-322-5p on IGF-1
expression, we transfected mouse C2C12 cells as
described in Methods. qPCR showed a significant
reduction in IGF-1 mRNA in miR-322-5p-mimic-
transfected cells, and this effect was reversed by
cotransfection with an antagomir (Fig. 3A). To deter-
mine whether human IGF-1 was also targeted by the
miRNA, LHCN-M2 cells were transfected with miR-
424-5p mimic. Again the expression of IGF-1 was sup-
pressed by miR-424-5p, but this suppression was not
as large as that obtained in murine cells. Although
median expression was higher in the presence of the
antagomir than in the miR-mimic-only-transfected
cells, this difference did not reach statistical signifi-
cance (Fig. 3B).
miR-424-5p reduces IGF-1 protein expression
To determine the effect of the miRNA on secreted
IGF-1 protein levels, we transfected human myoblasts
with miR-424-5p. Forty-eight hours later, growth
medium was replaced with serum-free medium for
24 h. The medium was aspirated and an ELISA per-
formed for human IGF-1. Consistent with reduced
mRNA, IGF-1 protein levels were reduced in miR-
424-5p-transfected cells compared to scrambled con-
trols (Fig. 3C). A similar reduction in secreted IGF-1
was observed by western blotting of separate samples
(Fig. 3D).
Discussion
Our data show that the hypertrophied RV from
MCT-treated rats had significantly reduced levels of
miR-322-5p and elevated expression of IGF-1. Fur-
thermore, we show that miR-322-5p binds to the
30UTR of IGF-1 and suppresses IGF-1 mRNA expres-
sion leading to a reduction in both IGF-1 mRNA and
protein. Together, these data imply that suppressed
miR-322-5p in the heart of MCT rats may contribute
to hypertrophy in part by increasing the expression of
IGF-1.
Insulin-like growth factor-1 signalling is well estab-
lished as an important promoter of protein synthesis
and a repressor of protein degradation. Through the
IGF-1 receptor, IGF-1 promotes the activation of Akt
and mTOR, both of which are master regulators of
protein synthesis (reviewed in [30]). Indeed, it has been
shown that treatment of isolated cardiac cells with 50–
100 nM IGF-1 causes a 70% increase in protein
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Fig. 1. (A) Pulmonary arterial pressure measured as mm of mercury (Hg) in five monocrotaline (MCT)-treated and seven PBS-treated rats.
(B) Right ventricle weight normalised to left ventricle and septum weight in nine MCT-treated and eight PBS-treated rats. (C) Normalised
miR-322-5p expression in MCT- and PBS-treated rats. D. IGF-1 expression levels in MCT- and PBS-treated rats.
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synthesis over insulin treatment [31]. The myocardium
produces IGF-1 locally, and evidence suggests that its
activity not only promotes growth, but also has a pro-
tective effect against myocardial apoptosis as shown in
a model of myocardial ischaemia and reperfusion [32].
Thus, IGF-1 functions to prevent myocyte loss and to
increase the size of cells [33], contributing to cardiac
hypertrophy both in normal cardiac growth and in dis-
ease states.
The reduction in RV miR-322-5p expression we
observed differs from previously reported changes in
miR-322-5p in cardiac hypertrophy. For example,
following 4-week aortic banding, miR-322 was found
to be elevated in the hypertrophying left ventricles
of mice; however, this same study saw no significant
increase in miR-424-5p in humans with end-stage
hypertrophic cardiomyopathy [34]. Another study, in
which rats had left anterior descending (LAD) artery
ligations causing development of an ischaemic zone
[35], noted elevated miR-322-5p expression in cardiac
tissue compared to sham-operated controls [36].
Other studies on PAH have also measured miR-322-
5p. For example, in response to MCT, Gubrij et al.
[37] showed a reduction in miR-322-5p in the lung
3 weeks after treatment as well as a small but signif-
icant reduction in the RV. These effects were similar
to those of Schlosser et al. [38] who showed signifi-
cantly reduced lung miR-322-5p and lower mean RV
miR-322-5p, although this did not reach statistical




























































































IGF-1 - Ago2 IP
Fig. 2. (A) (top) miR-322-5p mature sequence showing putative bind sites to IGF-1 30UTR with complimentary bases bolded and seed
sequence match site underlined; (bottom) miR-424-5p mature sequence showing multiple bind sites to IGF-1 coding region and 30UTR with
complimentary bases bolded and seed sequence match site underlined. (B) qPCR-measured enrichment of mRNA from immunoprecipitation
of argonaute 2 (Ago2) protein in cells transfected with miR-322-5p compared to control miRNA-transfected cells. (C) Expression of pMIR-
REPORT luciferase with IGF-1 30UTR sequence in cells transfected with miR-322-5p compared to scrambled controls.
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than that which we found, but both the time point
and the dose of MCT used in those studies vary
from the ones used here. Unlike MCT treatment,
hypoxia-induced PAH appears to increase RV miR-
322-5p in mice and to not change it in rats, suggest-
ing that the changes in miRNA profile are model-
specific [38]. The actual changes in the expression of
this miRNA in the RV in humans with PH remain
to be determined. The increase in miR-322-5p
observed in the hypoxia models is consistent with
the observations that miR-322/424 is a hypoxia-
induced miRNA, which has been shown to be
upregulated in cardiomyocytes during hypoxia-
induced apoptosis, and knockdown of the miRNA
had a cytoprotective effect [39].
Taken together, the variable expression of miR-322-
5p/miR-424-5p in hypertrophy suggests that it is under
a complex control with a number of both positive and
negative inputs and the measured expression level in
the heart will be a consequence of all of these inputs.
In our model, it is possible that the reduction in miR-
322-5p is a consequence of MCT treatment, directly or
as a consequence of increased afterload, and that this
reduction contributes to the RV hypertrophy in part
by elevating IGF-1. However, as we picked a single
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Fig. 3. (A) IGF-1 expression in C2C12 mouse myoblasts treated with miR-322-5p, miR-322-5p + antagomir inhibitor, or control miRNA. (B)
IGF-1 expression in LHCN-M2 human myoblasts treated with miR-424-5p, miR-424-5p + antagomir inhibitor, or control miRNA. (C) Secreted
IGF-1 protein levels normalised to total secreted protein in LHCN-M2 human myoblasts transfected with miR-424-5p or control miRNA. (D)
Western blot showing protein levels of IGF-1 in cells transfected with miR-424-5p (left) and control miRNA (right). Ponceau S staining of
membrane shown below.
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cannot determine whether miR-322-5p expression was
suppressed prior to the increase in IGF-1 or whether
there was a transient increase in miR-322-5p. It is
therefore possible that IGF-1 itself suppresses the
expression of miR-322-5p to reduce the pro-apoptotic
effects of this miRNA on cardiomyocytes [39]. Such
an effect would cause a positive feedback as IGF-1
suppressed miR-322-5p, which then allowed greater
translation of IGF-1 sustaining elevated IGF-1.
Such an explanation gains some support from a
recent study investigating circulating levels of miR-
322-5p in response to MCT [40]. This study showed
that miR-322-5p in circulation is elevated 1 week after
treatment and then decreases at 2 weeks only to
increase again by 6 weeks. However, the source of the
miR-322-5p in circulation is not clear as miR-424
expression is not restricted to the heart with expression
also found in the skeletal muscle, a more abundant tis-
sue than cardiac muscle.
Previous studies in the heart and other tissues have
shown that miR-322 contributes to the regulation of
IGF-1 signalling. For example, miR-424 was shown to
regulate the expression of the IGF-1 receptor (IGF-
1R) in epithelial cells as part of the regulation of
mammary involution [21]. The targeting of the IGF-
1R was confirmed in a study in which miR-322 or a
miR-322 sponge was expressed using an adeno-asso-
ciated virus (AAV) in the heart of diabetic or high-fat-
diet-fed mice. In this study, overexpression of the
miRNA led to a reduction in IGF-1R and sirtuin 4,
key components of the insulin signalling pathway, as
well as a reduction in Akt phosphorylation [22]. Our
data add to this study by indicating that IGF-1 is an
additional target of the miRNA, suggesting that
reduced expression of this miRNA will help to pro-
mote cardiac hypertrophy by increasing the level of
both IGF-1 and its receptor. It remains to be seen
which of these facets of the biology of IGF-1 has the
larger effect on cardiac growth.
Changes in miR-322-5p are not the only ones that
occur in cardiac hypertrophy that are likely to affect
the IGF-1 signalling system. For example, miR-223 is
a miRNA that is suppressed by hypoxia but targets
the IGF-1R [41]. Overexpression of this miRNA atten-
uated cardiac hypertrophy and suppressed IGF-1R
expression in analogous way to the effects of miR-322-
5p in response to MCT. However, it is interesting to
note that this miRNA is regulated in the opposite
direction to miR-322-5p in response to hypoxia but
targets at least one of the same genes, highlighting the
complexity of the system and the fact that multiple
miRNAs contribute to the regulation in individual
proteins [41]. Such complexity may account for the
differences in the observed changes in miR-424-5p
expression in PAH models.
The data also raise the potential of increasing miR-
424-5p expression in the heart to reduce cardiac hyper-
trophy at least in PAH. Ideally, this would be achieved
by a selective upregulation of the miRNA in the heart.
Increasing miRNA is more difficult than suppressing
their activity due to the processes involved in incorpo-
rating the miRNA into the RISC complex. However,
mimics are currently being used in clinical trials for a
range of conditions including cancer (reviewed in [42]).
Furthermore, direct cardiac injection of miRNA mim-
ics for miR-199a-3p and miR-590-3p has been shown
to enable myocardial repair [43] An alternative to
mimics is the use of viral delivery of an expression cas-
sette for the miRNA as described above for miR-322-
5p. However, given the potential for dynamic changes
in miR-424 described previously, the development of
this as an approach to reduce hypertrophy in PAH
would require a much more detailed analysis of miR-
424-5p expression in the heart during the development
of disease. Finally, any potential reduction in RV
hypertrophy has to be balanced against reduction in
pulmonary vascular remodelling.
The miRNAs target a vast array of genes at varying
efficiencies to fine-tune the proteome and thereby regu-
late multiple processes concurrently (reviewed in [44]).
As well as targeting IGF-1 and its receptor, miR-424
has been shown to potentiate TGF-b signalling via tar-
geting of SMAD7 (a negative regulator of canonical
TGF-b signalling) in lung [45], mammary [46] and
oesophageal epithelial cells [47]. In this case, reduced
miR-424 might be expected to reduce TGF-b-induced
hypertrophy [48], an effect opposite to that produced
by regulating IGF-1. However, in rat cardiac cells it
has been shown that miR-15b (a miRNA that shares
the same seed sequence as miR-322) targets compo-
nents required for TGF-b family signalling such as
SMAD2/3 as well as SMAD7, suggesting that it may
regulate the balance of TGF-b and BMP signalling.
Consequently, the effects of miR-424 on TGF-b/BMP
signalling are likely to be cell type- and context-speci-
fic. However, the specific capacity of miR-322 to regu-
late these components is not known [34]. Other
validated targets for miR-424 include cdc25, a compo-
nent required to move through the cell cycle and apop-
tosis inhibitor [49,50], and bcl-2, an anti-apoptotic
protein upregulated in several cancers [51,52].
Recently, miR-424-5p was also shown to reduce rRNA
production by targeting components of the RNA poly-
merase I pre-initiation complex [53]. Taken together,
these data suggest miR-424 is a promoter of cell quies-
cence and death, the loss of which can result in an
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increased proliferative capacity which can lead to an
oncogenic phenotype, or in the case of the nondividing
myocardium, hypertrophy.
Conclusion
Our data suggest that reduced miR-322-5p contributes
to the cardiac hypertrophy that occurs in PAH at least
in part by increasing the expression of IGF-1. This
increase in ligand, in combination with the increase in
receptor (IGF-1R) that others have identified,
increases the activity of the IGF-1/Akt axis leading to
increased protein synthesis and myocyte hypertrophy.
These data suggest that miR-322-5p expression in nor-
mal circumstances acts to limit protein synthesis as
part of the normal homoeostatic mechanisms. Whether
this restriction on protein synthesis in normal physiol-
ogy is removed only in response to pathological stim-
uli or whether the same mechanisms contribute to
normal physiological hypertrophy in response to exer-
cise remains to be determined.
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